Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Randomized, Two Parts, Dose-Finding Study To Evaluate The Safety, Tolerability and Immunogenicity Of An Inactivated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate (VLA2001), Against Covid-19 In Healthy Subjects

Next Previous
Trial Profile

A Phase I/II Randomized, Two Parts, Dose-Finding Study To Evaluate The Safety, Tolerability and Immunogenicity Of An Inactivated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate (VLA2001), Against Covid-19 In Healthy Subjects

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VLA 2001 (Primary) ; Aluminium hydroxide; CpG 1018
  • Indications COVID 2019 infections
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Valneva

Most Recent Events

  • 16 Jun 2022 Results published in the Journal of Infection
  • 19 Apr 2022 Status changed from active, no longer recruiting to completed.
  • 19 Jan 2022 According to an Valneva media release, sera from 30 participants from this Phase 1/2 trial VLA2001-201 were used in initial laboratory study demonstrating that serum antibodies induced by three doses of Valnevas inactivated COVID-19 vaccine candidate, VLA2001, neutralize the Omicron variant.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top